Zhengdong Jiang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7292910/publications.pdf

Version: 2024-02-01

23 papers	1,131 citations	430874 18 h-index	642732 23 g-index
23 all docs	23 docs citations	23 times ranked	2052 citing authors

#	Article	IF	Citations
1	Resveratrol and cancer treatment: updates. Annals of the New York Academy of Sciences, 2017, 1403, 59-69.	3.8	98
2	Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Molecular Cancer, 2017, 16, 131.	19.2	93
3	Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression. Cancer Letters, 2017, 385, 225-233.	7.2	89
4	Reactive Oxygen Species and Targeted Therapy for Pancreatic Cancer. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-9.	4.0	81
5	Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis. Oncotarget, 2015, 6, 20993-21003.	1.8	68
6	Loss of <scp>AMPK</scp> activation promotes the invasion and metastasis of pancreatic cancer through an <scp>HSF</scp>1â€dependent pathway. Molecular Oncology, 2017, 11, 1475-1492.	4.6	67
7	Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting <scp>SREBP</scp>1. Cell Proliferation, 2019, 52, e12514.	5.3	65
8	Resveratrol-Induced Downregulation of NAF-1 Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine via the ROS/Nrf2 Signaling Pathways. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-16.	4.0	63
9	YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine. Nutrients, 2016, 8, 546.	4.1	56
10	Resveratrol Inhibits ROS-Promoted Activation and Glycolysis of Pancreatic Stellate Cells via Suppression of miR-21. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-15.	4.0	54
11	Resveratrol in the treatment of pancreatic cancer. Annals of the New York Academy of Sciences, 2015, 1348, 10-19.	3.8	53
12	High glucose microenvironment accelerates tumor growth via SREBP1-autophagy axis in pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 302.	8.6	53
13	Activation of Nrf2 by Sulforaphane Inhibits High Glucose-Induced Progression of Pancreatic Cancer via AMPK Dependent Signaling. Cellular Physiology and Biochemistry, 2018, 50, 1201-1215.	1.6	49
14	Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer. Life Sciences, 2018, 208, 253-261.	4.3	40
15	Overexpression of Nodal induces a metastatic phenotype in pancreatic cancer cells via the Smad2/3 pathway. Oncotarget, 2015, 6, 1490-1506.	1.8	39
16	Hyperglycemia Promotes the Epithelial-Mesenchymal Transition of Pancreatic Cancer via Hydrogen Peroxide. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-9.	4.0	38
17	Lipoxin A4 reverses mesenchymal phenotypes to attenuate invasion and metastasis via the inhibition of autocrine TGF-Î²1 signaling in pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 2017, 36, 181.	8.6	32
18	The Relevance of Nrf2 Pathway and Autophagy in Pancreatic Cancer Cells upon Stimulation of Reactive Oxygen Species. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-11.	4.0	27

#	Article	IF	Citations
19	Î²2-Adrenogenic signaling regulates NNK-induced pancreatic cancer progression via upregulation of HIF-1Î±. Oncotarget, 2016, 7, 17760-17772.	1.8	17
20	Indometacin inhibits the proliferation and activation of human pancreatic stellate cells through the downregulation of COX-2. Oncology Reports, 2018, 39, 2243-2251.	2.6	17
21	Itraconazole inhibits invasion and migration of pancreatic cancer cells by suppressing TGF-Î²/SMAD2/3 signaling. Oncology Reports, 2018, 39, 1573-1582.	2.6	16
22	Norepinephrine enhances cell viability and invasion, and inhibits apoptosis of pancreatic cancer cells in a Notchâ€˜1â€˜dependent manner. Oncology Reports, 2018, 40, 3015-3023.	2.6	12
23	Pancreatic carcinoma-specific immunotherapy using novel tumor specific cytotoxic T cells. Oncotarget, 2016, 7, 83601-83610.	1.8	4